Xenetic Biosciences, Inc.XBIO
Price (close)
$2.47
Market cap
$5.8M
P/E
—
Revenue (TTM)
$3.3M
Net income
-$2.5M
Dividend yield
—
1-year total return
-23.8%
Net margin
-75.9%
Revenue growth
33.3%
Debt / equity
—
What Xenetic Biosciences, Inc. does.
innovative immuno-oncology technologies addressing difficult to treat cancers. Our proprietary DNase technology is designed to improve
outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (“NETs”), which are
involved in cancer growth, metastasis and progression, and contribute to immunotherapy, chemotherapy and radiotherapy resistance.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $436,942 | $1.2M | $1.7M | $2.5M | $2.5M | $3.0M |
| Net income | -$10.9M | -$5.6M | -$6.6M | -$4.1M | -$4.0M | -$2.7M |
| Free cash flow | — | — | — | — | — | — |
More on XBIO.
- Xenetic Biosciences, Inc. summary
- Xenetic Biosciences, Inc. financial statements
- Xenetic Biosciences, Inc. key metrics
- Xenetic Biosciences, Inc. health scores and style box
- Xenetic Biosciences, Inc. earnings
- Xenetic Biosciences, Inc. dividends
- Xenetic Biosciences, Inc. valuation
- Xenetic Biosciences, Inc. ownership and insiders
- Xenetic Biosciences, Inc. peers
Figures from Xenetic Biosciences, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.